Europe’s drug regulator said on Tuesday it had begun reviewing AstraZeneca Plc’s (AZN.L) application for antibody-based COVID-19 therapy, a key step towards approval of the treatment in the region, but gave no timeline for a conclusion.
Infections from COVID-19 are still rising in parts of the world including Europe. China posted a steep jump in daily COVID-19 infections on Tuesday, with new cases more than doubling from a day earlier to hit a two-year high.